Literature DB >> 20182439

Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?

W E Benitz1.   

Abstract

Medical and surgical interventions are widely used to close a persistently patent ductus arteriosus in preterm infants. Objective evidence to support these practices is lacking, causing some to question their usage. Emerging evidence suggests that treatments that close the patent ductus may be detrimental. This review examines the history of and evidence underlying these treatments. Neither individual trials, pooled data from groups of randomized-controlled trials, nor critical examination of the immediate consequences of treatment provide evidence that medical or surgical closure of the ductus is beneficial in preterm infants. These conclusions are supported by sufficient evidence. Neither continued routine use of these treatments nor additional clinical trials using similar designs seems to be justified. A definitive trial, comparing current standard management with novel strategies not primarily intended to achieve ductal closure, may be necessary to resolve doubts regarding the quality or conduct of prior studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182439     DOI: 10.1038/jp.2010.3

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  70 in total

1.  The Patent Ductus Arteriosus Problem: Infants Who Still Need Treatment.

Authors:  Jeff Reese; Matthew M Laughon
Journal:  J Pediatr       Date:  2015-08-24       Impact factor: 4.406

2.  Diagnosis and Management of Patent Ductus Arteriosus.

Authors:  Maria Gillam-Krakauer; Jeff Reese
Journal:  Neoreviews       Date:  2018-07

3.  Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants.

Authors:  Jonathan L Slaughter; Patricia B Reagan; Thomas B Newman; Mark A Klebanoff
Journal:  JAMA Pediatr       Date:  2017-03-06       Impact factor: 16.193

4.  Treatment and Nontreatment of the Patent Ductus Arteriosus: Identifying Their Roles in Neonatal Morbidity.

Authors:  Ronald I Clyman; Melissa Liebowitz
Journal:  J Pediatr       Date:  2017-07-11       Impact factor: 4.406

5.  Effects of prophylactic indomethacin in extremely low-birth-weight infants with and without adequate exposure to antenatal corticosteroids.

Authors:  Barbara Schmidt; Mary Seshia; Seetha Shankaran; Lindsay Mildenhall; Jon Tyson; Kei Lui; Tai Fok; Robin Roberts
Journal:  Arch Pediatr Adolesc Med       Date:  2011-07

6.  Therapeutic strategies, including a high surgical ligation rate, for patent ductus arteriosus closure in extremely premature infants in a North American centre.

Authors:  Gregory P Moore; Sarah L Lawrence; Gyaandeo Maharajh; Amanda Sumner; Isabelle Gaboury; Nick Barrowman; Brigitte Lemyre
Journal:  Paediatr Child Health       Date:  2012-04       Impact factor: 2.253

Review 7.  Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct.

Authors:  Mark A Turner
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

8.  Transcriptional profiling reveals ductus arteriosus-specific genes that regulate vascular tone.

Authors:  Elaine L Shelton; Gerren Ector; Cristi L Galindo; Christopher W Hooper; Naoko Brown; Irene Wilkerson; Elise R Pfaltzgraff; Bibhash C Paria; Robert B Cotton; Jason Z Stoller; Jeff Reese
Journal:  Physiol Genomics       Date:  2014-05-01       Impact factor: 3.107

Review 9.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

Review 10.  Patent ductus arteriosus in preterm infant: Basic pathology and when to treat.

Authors:  Abdulrahman M H Al Nemri
Journal:  Sudan J Paediatr       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.